Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofensine (RO 8-4650) is a potent **triple monoamine reuptake inhibitor** developed by Hoffmann-La Roche in the 1970s as a potential antidepressant. It inhibits the reuptake of **dopamine**, **norepinephrine**, and **serotonin** at their respective transporters, with primary effects on dopamine and norepinephrine. It is chemically a tetrahydroisoquinoline derivative. While found effective in human trials for depression, with relatively few side effects, it was discontinued from clinical development, possibly due to concerns about abuse potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofensine.